Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{60c6deb7209140a09a2cb409fd649b3b,
title = "Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation",
abstract = "Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.",
keywords = "Antibodies, Neutralizing, Biological Markers, Chemokine CCL2, Chemokine CXCL10, Drug Resistance, Gene Expression, Gene Expression Profiling, Humans, Immunologic Factors, Interferon-beta, Membrane Proteins, Multiple Sclerosis, Oligonucleotide Array Sequence Analysis, Reverse Transcriptase Polymerase Chain Reaction",
author = "Sellebjerg, {Finn Thorup} and M Krakauer and D Hesse and Ryder, {L P} and I Alsing and Jensen, {P E H} and Nils Koch-Henriksen and Anja Svejgaard and S{\o}rensen, {Per Soelberg}",
year = "2009",
doi = "10.1111/j.1468-1331.2009.02716.x",
language = "English",
volume = "16",
pages = "1291--8",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation

AU - Sellebjerg, Finn Thorup

AU - Krakauer, M

AU - Hesse, D

AU - Ryder, L P

AU - Alsing, I

AU - Jensen, P E H

AU - Koch-Henriksen, Nils

AU - Svejgaard, Anja

AU - Sørensen, Per Soelberg

PY - 2009

Y1 - 2009

N2 - Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.

AB - Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.

KW - Antibodies, Neutralizing

KW - Biological Markers

KW - Chemokine CCL2

KW - Chemokine CXCL10

KW - Drug Resistance

KW - Gene Expression

KW - Gene Expression Profiling

KW - Humans

KW - Immunologic Factors

KW - Interferon-beta

KW - Membrane Proteins

KW - Multiple Sclerosis

KW - Oligonucleotide Array Sequence Analysis

KW - Reverse Transcriptase Polymerase Chain Reaction

U2 - 10.1111/j.1468-1331.2009.02716.x

DO - 10.1111/j.1468-1331.2009.02716.x

M3 - Journal article

VL - 16

SP - 1291

EP - 1298

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 12

ER -

ID: 33228103